Видео ютуба по тегу Herceptin

Herceptin (trastuzumab) for HER2-Positive Breast and Stomach Cancer
Herceptin (trastuzumab) for HER2-Positive Breast and Stomach Cancer
Herceptin—a targeted antibody therapy for breast cancer
Herceptin—a targeted antibody therapy for breast cancer
Trastuzumab Deruxtecan for Breast Cancer | NEJM
Trastuzumab Deruxtecan for Breast Cancer | NEJM
Herceptin - the first monoclonal treatment for cancer
Herceptin - the first monoclonal treatment for cancer
Clinical usage of antibody: Herceptin (Antibody as breast cancer medicine)
Clinical usage of antibody: Herceptin (Antibody as breast cancer medicine)
Mayo Clinic Researchers Find Survival Improves When Herceptin is Used with Chemotherapy
Mayo Clinic Researchers Find Survival Improves When Herceptin is Used with Chemotherapy
Breast cancer | Part 1 | common symptoms and more.
Breast cancer | Part 1 | common symptoms and more.
Breast Cancer Drug Herceptin a Life Saver
Breast Cancer Drug Herceptin a Life Saver
Herceptin Gives Breast Cancer Survivor Second Chance at Life
Herceptin Gives Breast Cancer Survivor Second Chance at Life
Susan Desmond-Hellmann (UCSF): Herceptin and Drug Development
Susan Desmond-Hellmann (UCSF): Herceptin and Drug Development
Dr. José Baselga on Combining Pertuzumab (Perjeta) with Trastuzumab (Herceptin)
Dr. José Baselga on Combining Pertuzumab (Perjeta) with Trastuzumab (Herceptin)
Herceptin and Chemotherapy Treatment Combo Increases Survival Rates in Early Breast Cancer Patients
Herceptin and Chemotherapy Treatment Combo Increases Survival Rates in Early Breast Cancer Patients
Beyond anthracyclines and trastuzumab: cardiotoxicity of novel agents
Beyond anthracyclines and trastuzumab: cardiotoxicity of novel agents
Dr. Sramila Aithal Describes the HERceptin Adjuvant (HERA) Trial for HER2-Positive Breast Cancer
Dr. Sramila Aithal Describes the HERceptin Adjuvant (HERA) Trial for HER2-Positive Breast Cancer
PERSEPHONE: 6 vs. 12-month adjuvant trastuzumab in early breast cancer
PERSEPHONE: 6 vs. 12-month adjuvant trastuzumab in early breast cancer
Dr. Piccart on the Success of Trastuzumab
Dr. Piccart on the Success of Trastuzumab
Study of Atezolizumab with Pertuzumab and Trastuzumab in HER2- Positive Metastatic Breast Cancer
Study of Atezolizumab with Pertuzumab and Trastuzumab in HER2- Positive Metastatic Breast Cancer
Dr. Dennis Slamon reflects on the development of breast cancer drug Herceptin
Dr. Dennis Slamon reflects on the development of breast cancer drug Herceptin
Trial of proposed trastuzumab biosimilar, MYL-1401O vs herceptin
Trial of proposed trastuzumab biosimilar, MYL-1401O vs herceptin